Truist has revised its price target for GoodRx (GDRX, Financial), lowering it from $6.50 to $5.50, while maintaining a Hold rating on the stock. This adjustment comes as part of a broader analysis ahead of the first-quarter results for the Healthcare IT (HCIT) sector.
Although the HCIT industry typically remains insulated from widespread economic uncertainties, recent concerns about tariffs and a potential economic slowdown are contributing to increased market volatility. Such conditions pose challenges for high-beta, highly volatile sectors like Digital Health and Payviders.
While HCIT companies may not face direct tariff impacts, their clients—such as hospitals and pharmaceutical firms—are likely to experience supply chain cost increases or might opt to slow down their capital investments. This indirect exposure is prompting cautious sentiment among investors as they evaluate the sector's future performance.
